Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

NCT04196257 is registered in ClinicalTrials.gov with Bio-Path Holdings, Inc. as lead sponsor.

NCT NCT04196257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04196257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors
Lead sponsor
Bio-Path Holdings, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 19, 2022
Completion date
October 31, 2027
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, ovarian epithelial, endometrial cancer, fallopian tube neoplasms, peritoneal cancer, solid tumor, solid tumor, adult